Generex Biotechnology Corp Insiders
GNBTDelisted Stock | USD 0.0001 0.00 0.00% |
Generex Biotechnology employs about 15 people. The company is managed by 25 executives with a total tenure of roughly 149 years, averaging almost 5.0 years of service per executive, having 0.6 employees per reported executive. Breaking down Generex Biotechnology's management performance can provide insight into the firm performance.
Mark Fletcher CEO President CEO, General Counsel, Director |
Joseph Moscato Chairman Chairman of the Board and Presidentident, CEO |
Generex |
Generex Biotechnology Management Team Effectiveness
The company has return on total asset (ROA) of (0.4384) % which means that it has lost $0.4384 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.7271) %, meaning that it created substantial loss on money invested by shareholders. Generex Biotechnology's management efficiency ratios could be used to measure how well Generex Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.Generex Biotechnology Workforce Comparison
Generex Biotechnology Corp is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 41,410. Generex Biotechnology adds roughly 15.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Generex Biotechnology Notable Stakeholders
A Generex Biotechnology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Generex Biotechnology often face trade-offs trying to please all of them. Generex Biotechnology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Generex Biotechnology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark Fletcher | President CEO, General Counsel, Director | Profile | |
Joseph Moscato | Chairman of the Board and Presidentident, CEO | Profile | |
Eric Hofe | VP, Director and President of Antigen Express, Inc | Profile | |
Jacob Dagan | Executive Vice President Business Development. | Profile | |
Andrew Ro | Senior Vice President of Investments, Chief Investment Officer, Director | Profile | |
Marshal Schictman | Executive Vice President General Counsel | Profile | |
Richard Purcell | Senior Vice President of Research & Drug Development. | Profile | |
Mark Corrao | CFO, Treasurer | Profile | |
Stephen Fellows | CFO | Profile | |
David Brusegard | COO and Secretary | Profile | |
James Anderson | Independent Director | Profile | |
Gary Lyman | Independent Director | Profile | |
Mark Prioletti | Independent Interim Director | Profile | |
Kevin Centofanti | Director | Profile | |
Craig Eagle | Independent Director | Profile | |
Lawrence Salvo | Director | Profile | |
Omar Gzouli | Independent Interim Director | Profile | |
Andrew Greene | Director | Profile | |
Brian McGee | Independent Director | Profile | |
Terry Thompson | Chief Officer | Profile | |
Jason Terrell | Chief Scientific Officer, Chief Medical Officer | Profile | |
Esq CPA | Chief Officer | Profile | |
Anthony Dolisi | Chief Officer | Profile | |
Todd Falls | IR Contact Officer | Profile | |
Michelle Starr | Chief Officer | Profile |
About Generex Biotechnology Management Performance
The success or failure of an entity such as Generex Biotechnology often depends on how effective the management is. Generex Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Generex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Generex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. On June 6, 2022, the involuntary petition was approved by the Court. GENEREX BIOTECHNOLOGY operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 15 people.
The data published in Generex Biotechnology's official financial statements usually reflect Generex Biotechnology's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Generex Biotechnology. For example, before you start analyzing numbers published by Generex accountants, it's critical to develop an understanding of what Generex Biotechnology's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Generex Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Generex Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Generex Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Generex Biotechnology Corp. Please utilize our Beneish M Score to check the likelihood of Generex Biotechnology's management manipulating its earnings.
Generex Biotechnology Workforce Analysis
Traditionally, organizations such as Generex Biotechnology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Generex Biotechnology within its industry.Generex Biotechnology Manpower Efficiency
Return on Generex Biotechnology Manpower
Revenue Per Employee | 177.4K | |
Revenue Per Executive | 106.5K | |
Net Loss Per Employee | 2.2M | |
Net Loss Per Executive | 1.3M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Generex Biotechnology information on this page should be used as a complementary analysis to other Generex Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Generex OTC Stock
If you are still planning to invest in Generex Biotechnology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Generex Biotechnology's history and understand the potential risks before investing.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |